[{"id":"27751dcd-f28f-4f36-b8db-e4042ae9fc77","acronym":"CVL006-T1002","url":"https://clinicaltrials.gov/study/NCT07157956","created_at":"2025-09-13T08:47:52.158Z","updated_at":"2025-09-13T08:47:52.158Z","phase":"Phase 1/2","brief_title":"CVL006 Combination Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT07157956 - CVL006-T1002","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 08/12/2028","primary_completion_date":" 08/12/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-09-05"},{"id":"eebefa81-1645-4e61-b40b-7636aef12cd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012031","created_at":"2025-06-14T13:57:15.769Z","updated_at":"2025-06-14T13:57:15.769Z","phase":"Phase 1/2","brief_title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","source_id_and_acronym":"NCT07012031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ERBB3","pipe":" | ","alterations":" HER-2 overexpression","tags":["KRAS • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/06/2025","start_date":" 06/06/2025","primary_txt":" Primary completion: 06/14/2027","primary_completion_date":" 06/14/2027","study_txt":" Completion: 06/14/2027","study_completion_date":" 06/14/2027","last_update_posted":"2025-06-11"},{"id":"cc900cf1-cbd5-4b72-929f-5a7f0c8da6dd","acronym":"KEYNOTE-797","url":"https://clinicaltrials.gov/study/NCT04042701","created_at":"2021-01-18T19:49:50.989Z","updated_at":"2025-02-25T12:37:23.766Z","phase":"Phase 1","brief_title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04042701 - KEYNOTE-797","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"2da5468a-79d4-4eeb-942f-5b05fa2fb4d8","acronym":"CERTIS1","url":"https://clinicaltrials.gov/study/NCT05417594","created_at":"2022-06-14T22:56:26.797Z","updated_at":"2025-02-25T14:08:54.388Z","phase":"Phase 1/2","brief_title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT05417594 - CERTIS1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk) • AZD9574"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-19"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"e6f0f0cd-c6bf-46b7-8b76-a1dbcf03e0df","acronym":"HER2CLIMB-04","url":"https://clinicaltrials.gov/study/NCT04539938","created_at":"2021-07-05T17:32:09.274Z","updated_at":"2025-02-25T14:02:02.863Z","phase":"Phase 2","brief_title":"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer","source_id_and_acronym":"NCT04539938 - HER2CLIMB-04","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-19"},{"id":"ebc393d7-e583-45ba-8ae9-46feb62c3abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376878","created_at":"2022-05-17T12:54:20.623Z","updated_at":"2025-02-25T14:08:52.333Z","phase":"Phase 4","brief_title":"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","source_id_and_acronym":"NCT05376878","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/21/2022","start_date":" 12/21/2022","primary_txt":" Primary completion: 02/25/2026","primary_completion_date":" 02/25/2026","study_txt":" Completion: 02/25/2026","study_completion_date":" 02/25/2026","last_update_posted":"2025-02-18"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"e2a7e1c5-e873-49a1-9d76-b61c5d386ab0","acronym":"DESTINY-Breast07","url":"https://clinicaltrials.gov/study/NCT04538742","created_at":"2021-01-18T21:43:10.527Z","updated_at":"2025-02-25T13:53:25.796Z","phase":"Phase 1/2","brief_title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT04538742 - DESTINY-Breast07","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-14"},{"id":"8ec2e9d9-3e26-4f1f-93c7-9dcc604ae768","acronym":"ADAPTHER2-IV","url":"https://clinicaltrials.gov/study/NCT05704829","created_at":"2023-01-30T15:59:31.869Z","updated_at":"2025-02-25T12:29:21.471Z","phase":"Phase 2","brief_title":"NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer","source_id_and_acronym":"NCT05704829 - ADAPTHER2-IV","lead_sponsor":"West German Study Group","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 402","initiation":"Initiation: 02/05/2024","start_date":" 02/05/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-11"},{"id":"91d133a9-9ef3-48c9-bf10-dee2c3a46301","acronym":"DO-01","url":"https://clinicaltrials.gov/study/NCT06819007","created_at":"2025-02-25T15:31:02.759Z","updated_at":"2025-02-25T15:31:02.759Z","phase":"Phase 3","brief_title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer","source_id_and_acronym":"NCT06819007 - DO-01","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 582","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 11/01/2028","primary_completion_date":" 11/01/2028","study_txt":" Completion: 01/31/2032","study_completion_date":" 01/31/2032","last_update_posted":"2025-02-11"},{"id":"e4341e18-0636-4930-ba0b-0c9da6c26d3f","acronym":"DESTINY-BTC01","url":"https://clinicaltrials.gov/study/NCT06467357","created_at":"2025-02-25T15:45:41.147Z","updated_at":"2025-02-25T15:45:41.147Z","phase":"Phase 3","brief_title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","source_id_and_acronym":"NCT06467357 - DESTINY-BTC01","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 620","initiation":"Initiation: 08/12/2024","start_date":" 08/12/2024","primary_txt":" Primary completion: 06/12/2028","primary_completion_date":" 06/12/2028","study_txt":" Completion: 05/16/2029","study_completion_date":" 05/16/2029","last_update_posted":"2025-02-11"},{"id":"64837254-ecf8-44d3-8267-0595bd882719","acronym":"","url":"https://clinicaltrials.gov/study/NCT05633979","created_at":"2022-12-01T15:57:19.166Z","updated_at":"2025-02-25T15:27:45.382Z","phase":"Phase 1","brief_title":"Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer","source_id_and_acronym":"NCT05633979","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • UGT1A1","pipe":"","alterations":" ","tags":["HER-2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/09/2023","start_date":" 02/09/2023","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2032","study_completion_date":" 12/31/2032","last_update_posted":"2025-02-10"},{"id":"f6a27acf-7978-4c4b-a907-56c547d54b2a","acronym":"Morpheus-TNBC","url":"https://clinicaltrials.gov/study/NCT03424005","created_at":"2021-01-18T16:53:25.262Z","updated_at":"2025-02-25T15:17:38.740Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03424005 - Morpheus-TNBC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • PIK3CA","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation","tags":["HER-2 • PD-L1 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 05/03/2028","primary_completion_date":" 05/03/2028","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2025-02-10"},{"id":"95c0229a-8b91-4b07-bbd8-e69278f6a209","acronym":"DESTINY-Gastric03","url":"https://clinicaltrials.gov/study/NCT04379596","created_at":"2021-01-18T21:09:02.628Z","updated_at":"2025-02-25T16:32:08.037Z","phase":"Phase 2","brief_title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","source_id_and_acronym":"NCT04379596 - DESTINY-Gastric03","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 06/03/2020","start_date":" 06/03/2020","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-02-07"},{"id":"bbd54b62-457a-494d-90d2-1614ae83c172","acronym":"DESTINY-Breast08","url":"https://clinicaltrials.gov/study/NCT04556773","created_at":"2021-01-18T21:46:53.987Z","updated_at":"2025-02-25T16:45:09.442Z","phase":"Phase 1","brief_title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04556773 - DESTINY-Breast08","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 12/04/2025","study_completion_date":" 12/04/2025","last_update_posted":"2025-02-05"},{"id":"c6f6111f-3721-44d3-8d28-6c42b01ad58a","acronym":"DESTINY-Breast11","url":"https://clinicaltrials.gov/study/NCT05113251","created_at":"2021-11-09T12:53:05.265Z","updated_at":"2025-02-25T13:54:06.394Z","phase":"Phase 3","brief_title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","source_id_and_acronym":"NCT05113251 - DESTINY-Breast11","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 927","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 03/12/2025","primary_completion_date":" 03/12/2025","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-05"},{"id":"f4adf1be-e9f2-4aec-9718-ca80187e66aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294628","created_at":"2021-01-18T20:50:17.525Z","updated_at":"2025-02-25T17:36:34.350Z","phase":"Phase 1","brief_title":"Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer","source_id_and_acronym":"NCT04294628","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-29"},{"id":"08d1e6e8-fb84-46e5-ab28-7d30c69b7fb4","acronym":"DS8201-A-U105","url":"https://clinicaltrials.gov/study/NCT03523572","created_at":"2024-06-16T01:34:24.698Z","updated_at":"2025-02-25T14:26:56.311Z","phase":"Phase 1","brief_title":"Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer","source_id_and_acronym":"NCT03523572 - DS8201-A-U105","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/02/2018","start_date":" 08/02/2018","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2025-01-27"},{"id":"8cbb7e4f-640b-4398-856e-ad61eabb3ed4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06767436","created_at":"2025-02-26T07:14:38.945Z","updated_at":"2025-02-26T07:14:38.945Z","phase":"","brief_title":"A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer","source_id_and_acronym":"NCT06767436","lead_sponsor":"Yonsei University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/05/2024","start_date":" 11/05/2024","primary_txt":" Primary completion: 11/04/2025","primary_completion_date":" 11/04/2025","study_txt":" Completion: 11/04/2025","study_completion_date":" 11/04/2025","last_update_posted":"2025-01-09"},{"id":"e1db77e0-90c7-4f64-afe7-e9f653e16ebf","acronym":"ARTEMIDE-Gastric01","url":"https://clinicaltrials.gov/study/NCT06764875","created_at":"2025-02-26T07:06:51.440Z","updated_at":"2025-02-26T07:06:51.440Z","phase":"Phase 3","brief_title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","source_id_and_acronym":"NCT06764875 - ARTEMIDE-Gastric01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 840","initiation":"Initiation: 03/28/2025","start_date":" 03/28/2025","primary_txt":" Primary completion: 04/27/2029","primary_completion_date":" 04/27/2029","study_txt":" Completion: 12/09/2030","study_completion_date":" 12/09/2030","last_update_posted":"2025-01-09"},{"id":"6fb8362c-e7e1-47e4-848c-a1f5eb984935","acronym":"KEYNOTE-G08","url":"https://clinicaltrials.gov/study/NCT05824975","created_at":"2024-01-29T17:20:35.977Z","updated_at":"2025-02-25T16:18:44.543Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","source_id_and_acronym":"NCT05824975 - KEYNOTE-G08","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 358","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 11/12/2025","primary_completion_date":" 11/12/2025","study_txt":" Completion: 04/24/2027","study_completion_date":" 04/24/2027","last_update_posted":"2024-11-25"},{"id":"b8fdfff2-f67c-48fd-9e76-9ef9443b1f2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05480384","created_at":"2022-07-29T15:55:22.037Z","updated_at":"2025-02-25T15:00:32.371Z","phase":"Phase 2","brief_title":"Adjuvant Trastuzumab Deruxtecan (Enhertu) \u0026 Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus \u0026 Gastroesophageal Junction","source_id_and_acronym":"NCT05480384","lead_sponsor":"Brown University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-11-25"},{"id":"fcdaa581-7698-4699-bff1-a8e70321bccc","acronym":"DESTINY-CRC02","url":"https://clinicaltrials.gov/study/NCT04744831","created_at":"2021-02-09T13:53:02.487Z","updated_at":"2025-02-25T14:59:42.256Z","phase":"Phase 2","brief_title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04744831 - DESTINY-CRC02","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • TMB • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 overexpression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type","tags":["EGFR • HER-2 • BRAF • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 overexpression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 10/08/2024","study_completion_date":" 10/08/2024","last_update_posted":"2024-11-19"}]